术前短程放疗后巩固化疗治疗局部晚期直肠癌的Meta分析
该Meta分析纳入7项研究共1865例局部晚期直肠癌患者,比较术前短程放疗后巩固化疗(SCRT/CCT)与常规长程放化疗(LCCRT)。结果显示SCRT/CCT组病理完全缓解率更高,ypT3-4期和淋巴结阳性比例更低,无病生存期更优,总生存率和毒性相似。作者推荐SCRT/CCT作为可选的新辅助治疗方案。
要点
- SCRT/CCT组病理完全缓解率高于LCCRT组(RR=1.74,95%CI 1.41-2.15,P<0.01)。
- SCRT/CCT组ypT3-4期(RR=0.88,95%CI 0.80-0.97,P=0.01)和淋巴结阳性(RR=0.83,95%CI 0.71-0.98,P=0.02)比例更低。
- SCRT/CCT组无病生存期更优(RR=1.10,95%CI 1.02-1.18,P=0.01),总生存率和毒性两组相似。
核心结论
- 基于SCRT/CCT组更好的病理结局和无病生存期,作者推荐术前短程放疗后巩固化疗作为局部晚期直肠癌的可选新辅助治疗。
研究设计与样本
- 本研究为Meta分析,检索PubMed、EMBASE、MEDLINE和Cochrane Library数据库,最终纳入7项研究共1865例局部晚期直肠癌患者,采用RevMan 5.3计算合并风险比(RR)及95%置信区间(CI)。
主要发现
- 与LCCRT相比,SCRT/CCT组病理完全缓解率更高(RR=1.74,95%CI 1.41-2.15,P<0.01)。
- SCRT/CCT组ypT3-4期疾病比例更低(RR=0.88,95%CI 0.80-0.97,P=0.01),淋巴结阳性疾病比例也更低(RR=0.83,95%CI 0.71-0.98,P=0.02)。
- SCRT/CCT组无病生存期更优(RR=1.10,95%CI 1.02-1.18,P=0.01),总生存率、毒性和手术方式两组相似。
关键数值与推荐
- 主要终点为病理结局,次要终点包括生存率、保肛率、R0切除率和毒性。
- SCRT/CCT组病理完全缓解率RR=1.74(95%CI 1.41-2.15,P<0.01),ypT3-4期RR=0.88(95%CI 0.80-0.97,P=0.01),ypN+期RR=0.83(95%CI 0.71-0.98,P=0.02),无病生存期RR=1.10(95%CI 1.02-1.18,P=0.01)。
临床怎么用
- 作者推荐术前短程放疗后巩固化疗作为局部晚期直肠癌的可选新辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of consolidation chemotherapy to preoperative short-course radiotherapy during the prolonged interval between the completion of radiation and surgery in locally advanced rectal cancer (LARC) could enhance pathologic response and might act on potential micrometastasis. We performed this meta-analysis to evaluate whether short-course radiotherapy followed by consolidation chemotherapy (SCRT/CCT) could be a neoadjuvant treatment option compared with conventional long-course chemoradiotherapy (LCCRT). METHODS: We searched the PubMed, EMBASE, MEDLINE, and Cochrane Library databases. The primary endpoints were pathological outcomes, and the secondary endpoints included survival rate, sphincter preservation rate, R0 resection rate and toxicity. RevMan 5.3 was used to calculate pooled risk ratio (RRs) and 95% confidence intervals (CIs). RESULTS: A total of seven eligible studies and 1865 participants were included in this meta-analysis. Compared with the LCCRT, SCRT/CCT increased pathologic complete response (pCR) rate [RR = 1.74, 95% CI (1.41, 2.15), P < 0.01] and led to a lower proportion of patients with adjuvant pathologic tumor stage 3-4 (ypT3-4) disease [RR = 0.88, 95% CI (0.80, 0.97), P = 0.01] or lymph node positive (ypN +) disease [RR = 0.83, 95% CI (0.71, 0.98), P = 0.02]. In addition, the disease-free survival (DFS) was better in SCRT/CCT group [RR = 1.10, 95% CI (1.02, 1.18), P = 0.01], while overall survival rate and toxicity and surgical procedures were similar between two groups. CONCLUSION: Based on better pathological outcomes and DFS in SCRT/CCT group, we recommended preoperative short-course radiotherapy followed by consolidation chemotherapy as the optional neoadjuvant treatment for LARC.
引用
- Wu H, Fan C, Fang C, et al. Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis. Radiat Oncol. 2022. PMID: 35073940. doi:10.1186/s13014-021-01974-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。